36.01 -0.00 (-0.00%)
After hours: 5:35PM EDT
|Bid||36.01 x 900|
|Ask||36.40 x 900|
|Day's Range||34.94 - 36.69|
|52 Week Range||14.56 - 52.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.00|
Should You Be Watching PTC Therapeutics? Wall Street analysts estimate that PTC Therapeutics (PTCT) will generate revenues of $66.1 million in the second quarter, which represents a 37.9% YoY (year-over-year) growth. PTC Therapeutics’ Emflaza, which was launched in May 2017, primarily pushed its revenue growth.
In June, PTC Therapeutics (PTCT) presented its updated interim clinical data from the Phase 1 FIREFISH trial, which is evaluating the safety profile of risdiplam (RG7916) in babies with type 1 SMA (spinal muscular atrophy).
In June, the Committee for Medicinal Products for Human Use (or CHMP) of the European Medicines Agency (or EMA) recommended a positive opinion for the expansion of Translarna’s indication to include ambulatory children between the ages of two and five years with nonsense mutation Duchenne muscular dystrophy. The CHMP recommendation was based on data from the PTC Therapeutics Study 030.
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Foundation Medicine, Sarepta Therapeutics, and PTC Therapeutics reported market-moving news that every biotech investor ought to know about.
PTC Therapeutics spiked Wednesday after an analyst suggested it and Roche could rout Biogen and Ionis Pharmaceuticals in treating spinal muscular atrophy.
Sarepta shares were up $10.23 -- or 7.11% -- to $154.16 in mid-afternoon trading Wednesday after adding 36.8% Tuesday after the firm disclosed impressive test results for its new gene therapy designed to cure a rare form of muscular dystrophy. , which took a 30.6% hit Tuesday on Sarepta's announcement, regained some of its losses and rebounded 6.26% to $35.32 as of Wednesday afternoon. Zhong anticipates Sarepta will continue to rally, as investors are excited about the quality of findings on the gene therapy's effectiveness, as well as about the drug's market potential.
PTC Therapeutics shares are spiking following intriguing trial data; however, it's not the only competitor working on better treatments for SMA.
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
Sarepta Therapeutics Inc. soared nearly 40% in Tuesday trading after publishing impressive results for a new gene therapy designed to treat a rare form of muscular dystrophy. However, the news pushed shares of rival drugmaker PTC Therapeutics Inc.
Biogen and Ionis Crash on PTC Therapeutics' Promising DataPTC Therapeutics presented positive data on its SMA drug under trial
PTC Therapeutics' (PTCT) shares rally on encouraging preliminary data from a pivotal study evaluating risdiplam in babies with spinal muscular atrophy.
The S&P 500’s top losses on June 18 were: Biogen (BIIB) declined 5.2%. Comcast Corp A (CMCSA) declined 3.8%. AmerisourceBergen (ABC) declined 3.5%. Intel (INTC) declined 3.4%. CVS (CVS) declined 3.4%. Biogen
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Shares of PTC Therapeutics saw big gains in Monday trading after announcing positive data with its partner Roche on their spinal muscular atrophy drug, risdiplam. Shares of Catalyst Biosciences were plummeting after announcing a worrisome update on its ongoing phase ½ trial investigating its next generation Factor IX (FIX) candidate CB 2679d/ISU304. PTC Therapeutics, Inc. shares closed up 27.51% on about 11.7 million shares traded yesterday.
PTC Therapeutics Inc’s (NASDAQ:PTCT): PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. With the latest financial yearRead More...
PTC Therapeutics, Inc. (NASDAQ: PTCT ) traded sigificantly higher Monday after having published a positive update from its risdiplam trial in type 1 SMA babies. The Rating William Blair analyst Raju Prasad ...
Biogen tumbled 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it. Biogen has a few new drugs in the pipeline, including one that could help the company defend its leadership in MS drug therapy, but these are at least two years away reaching the market. Biogen BIIB tumbled as much as 6 percent on Monday, after a rival drugmaker reported its experimental drug for spinal muscular atrophy helped a majority of babies who received it.
PTC Therapeutics Inc. shares rose to their highest price since August 2015 after the company said its experimental drug for spinal muscular atrophy helped the vast majority of babies who got the treatment. Over the weekend the company reported that after 182 days of treatment, 91 percent of babies on the drug improved more than four points on a scale that measures motor milestone developments in patients with a form of spinal muscular atrophy, or SMA. Spinal muscular atrophy is a rare disease that progressively takes away people’s physical strength and their ability to walk, eat and breathe.
A drug being co-developed by Roche to treat spinal muscular atrophy (SMA) helped improve development scores in babies with the genetic disease, a study released on Monday showed, as the race heats up for therapies destined to be among the drug industry's most expensive. PTC Therapeutics, which struck a licensing deal with Roche in 2011 for its SMA programme, said more than 90 percent of babies with severe Type 1 SMA given the RG7916 drug achieved a greater than four-point increase in a test to measure their neuromuscular progress six months after treatment began. Novartis is also quickly advancing in the SMA field with its $8.7 billion acquisition this year of U.S.-based Avexis that is working on a gene therapy for the disorder.
soared in premarket trading on Monday, June 18, after the biotech firm over the weekend presented updated interim clinical data on spinal muscular atrophy (SMA) drug risdiplam. The Chop-Intend is an assessment of motor skill in SMA Type 1. South Plainfield, N.J.-based PTC is collaborating with Roche Holdings AG and the SMA Foundation on the program.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! JD.Com Inc(ADR) (NASDAQ: JD ) was trading higher by ...